FDA Electronic Submission Deadlines Becoming Pixilated
This article was originally published in The Pink Sheet Daily
Executive Summary
Mandated electronic submissions likely to be staggered as agency says it’s not feasible to describe and implement electronic formats that apply to all submissions in one guidance.
You may also be interested in...
US OTC Monograph Reform Enters Electronic Age With Draft Guidance On Submission Formats
Submissions go to one of two addresses: OMORs, for changes or additions to monograph formulations and indications, go to the CDER NextGen Portal, and data, information and public comments on proposed or interim final orders go to OTC Monographs@FDA.
Some Adverse Events For Generics Still Should Not Be Submitted Through eCTD Portal, US FDA Says
Implementation of eCTD regulations for commercial INDs did not change system for submitting premarket bioavailability/bioequivalence study reports intended to support ANDA approval, agency clarifies.
Some Adverse Events For Generics Still Should Not Be Submitted Through eCTD Portal, US FDA Says
Implementation of eCTD regulations for commercial INDs did not change system for submitting premarket bioavailability/bioequivalence study reports intended to support ANDA approval, agency clarifies.